Ortho Evra lawsuit settled for $1.25m as J&J tries to avoid public trials

October 26th, 2007 by Scott Thomas

Ortho Evra manufacturer, Johnson & Johnson, recently settled a with the family of a 14-year-old girl killed by the defective birth control . The case is just one of many Ortho Evra lawsuits settled by Johnson & Johnson prior to going trial.


It likely hints at the company’s desire to avoid trials where its actions -or lack thereof – regarding safety problems with the defective Ortho Evra birth control patch could be called into question.

When was introduced in 2002, Johnson and Johnson touted the once-weekly as a convenient alternative to daily oral contraceptive pills. The drug’s original safety label stated that the ’s health risks were similar to those related to oral contraceptives.

But in 2005, the Food & Drug Administration warned that women using were exposed to approximately 60 percent more estrogen than those who used oral contraceptive pills. High levels of estrogen can greatly increase the risk of developing , heart attacks, strokes and other serious injuries. As of November 2005, the FDA had received twenty-one reports of life-threatening and other ailments associated with the use of .

Then in 2006, a study was published that showed women using were twice as likely to suffer as those taking oral birth control pills. That study prompted the FDA to request a change on the label to include a stronger safety warning.

Since then, has been named in well over 2,000 lawsuits, and the suit filed by 14-year-old Alycia Brown’s family is one of them. According to Bloomberg News, Alycia died in May 2004 from two in her lungs that developed after she had been using the birth control for several weeks.

According to court records obtained by Bloomberg, Johnson & Johnson settled with her family for $1.25 million. The court records said that Johnson & Johnson did not admit that had caused Alycia’s death, and that the company settled in order to avoid litigation. Neither Johnson & Johnson nor Alycia’s family would comment to Bloomberg, as both sides had signed a confidentiality agreement.

Johnson & Johnson is likely desperate to keep such agreements secret because it has been accused of ignoring warning signs that was dangerous. There is evidence that such accusations are true, including the testimony of Joe Lippman, a former employee of and a plaintiff in a whistle blower against Johnson & Johnson.

Lippman raised concerns over “dangerously high levels of estrogen” that users of the were exposed to in the late 1990s. Lippman, who was fired in 2006, claims his concerns were ignored.

October 25th, 2007

blog comments powered by Disqus

Comments are moderated and generally will be posted if they are on-topic and not abusive.